Navigation Links
Combination therapy more effective for enlarged prostate
Date:3/2/2010

DALLAS March 3, 2010 Like any successful team effort, the best qualities of two drugs commonly prescribed for enlarged prostate yielded better results than either of the medicines alone, according to a new study from UT Southwestern Medical Center.

The findings, published in a recent issue of the journal European Urology, compared treatments for three groups of study participants with enlarged prostates over four years. The study, which included more than 4,800 men, is one of the first to compare single and combo medication regimens in such a large group.

The first group of study participants received the drug dutasteride; the second group received tamsulosin; and the third received a combination of the two medicines.

"We found the combination therapy to be superior at reducing risk of BPH progression," said Dr. Claus Roehrborn, chairman of urology at UT Southwestern and lead author of the study. "The two medications joined forces in terms of symptom control. On the strengths of both dutasteride and tamsulosin, participants reported fewer symptoms, and we observed a 25 percent reduction in prostate volume."

Dr. Roehrborn added that subjects who received the combination therapy also showed a 50 percent reduction of prostate-specific antigen (PSA), a protein produced by both cancerous and noncancerous prostate tissue. PSA levels can be an indication of increased risk of cancer because cancer cells usually make more PSA than do benign cells, causing PSA levels in the blood to rise. Should PSA levels continue to rise after beginning therapy, patients should be monitored closely because the combination medicines do lower PSA readings, Dr. Roehrborn said.

Enlarged prostate, also called benign prostatic hyperplasia (BPH), is a common urologic condition that affects about 50 percent of men between the ages of 51 and 60 and up to 90 percent of men over the age of 80.

Symptoms of the condition can be prolonged and severe. Prostate enlargement creates pressure on the urethra, making it difficult to urinate, which can lead to acute urinary retention. This retention causes a host of other problems, including extreme discomfort and infections.

Researchers also looked at the data to determine if the number of study participants needing surgery for BPH decreased with the combination medication regimen. Compared with tamsulosin alone, the combination of drugs reduced the incidence of acute urinary retention by 67 percent and reduced the need for BPH-related surgery by 70 percent.

"We found a 65 percent decrease in the relative risk of acute urinary retention or BPH-related surgery compared with tamsulosin alone and just over a 19 percent reduction compared with dutasteride alone," said Dr. Roehrborn.

Those taking the combination of drugs also were less likely than those in the other two groups to discontinue therapy, he said. Participants themselves noted that the combo medicines were most effective at reducing symptoms.

"There is currently no combination drug for doctors to prescribe for these patients," Dr. Roehrborn said. "This research should provide physicians better information when they decide on a course of treatment for patients with BPH."


'/>"/>

Contact: Katherine Morales
katherine.morales@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. WHI data confirm short-term heart disease risks of combination menopausal hormone therapy
2. Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling
3. New Drugs, New Combinations Fight Breast Cancer
4. Multiple myeloma patients experience high response rate with new 3-drug combination
5. New combination therapy could deliver powerful punch to breast cancer
6. Inventive combination of research approaches identifies new target for treating leukemia
7. Combination of PET/CT tests can expedite diagnosis of lung cancer in a fast-track setting
8. Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
9. Nexavar in Combination With Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival in Patients With Advanced Breast Cancer in Phase 2 Study
10. More Sleep & Less Sex - A Losing Combination
11. Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2017)... St. Louis, MO (PRWEB) , ... August 22, 2017 , ... ... and career fairs to help healthcare employers connect with physicians and advanced practitioners like ... of virtual career fairs in August through November of this year. The ...
(Date:8/21/2017)... Aliso Viejo, CA (PRWEB) , ... August 21, 2017 , ... ... Pixel Film Studios. Editors can quickly and easily add washed color grades to ... an image. The LUT changes every pixel’s color to the corresponding color indicated by ...
(Date:8/21/2017)... , ... August 21, 2017 , ... ... recognized community involvement program serving the people of Michigan. The new initiative fundraises ... 120 years at the very forefront of animal protection and welfare by addressing ...
(Date:8/21/2017)... ... 2017 , ... San Diego physician and surgeon Dr. James Veltmeyer, author of ... candidacy for the 52nd Congressional District currently held by Representative Scott Peters. , ... country at age eleven after suffering homelessness and hardship in a distant land, I ...
(Date:8/20/2017)... (PRWEB) , ... August 20, 2017 , ... ... the HIPAA ComplyPAK™ Compliance Management System has assisted multiple clients in ... Certified Public Accountants, Service Organization Control Level 2 (AICPA SOC Level 2), and ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... 1, 2017   CerSci Therapeutics , a non-opioid ... , has received notice from the National Institute ... Health (NIH) that it has been awarded a Direct-to-Phase ... $650,000 in 2017 with an additional $1,000,000 to follow ... Drug application of their lead non-opioid drug candidate CT-044 ...
(Date:7/28/2017)... Inc. ("Hill-Rom") (NYSE: HRC), today announced financial results for ... updated its financial outlook for fiscal 2017. ... quarter, Hill-Rom reported earnings of $0.09 per diluted share ... period. These results reflect after-tax special items, including a ... the non-cash write-down of assets associated with the planned ...
(Date:7/26/2017)... Colo. , July 26, 2017 E.I. ... Guttridge and the Bimini SharkLab to custom design the worlds ... images of sharks in their native habitat. In preparation ... Discovery Channel,s Shark Week, Dr. Guttridge approached EIMI ... take pregnancy diagnosis directly to hammerhead sharks underwater. ...
Breaking Medicine Technology: